Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.
Search Results: Treatment + Colorectal Cancer + Stage 4 (11 results)
Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers
Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers
This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers.
Treatment
Treatment study for people with advanced cancer with an APC or AXIN1 mutation
A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation
This study is looking at how well the research drug REC-4881 works and how safe it is for the treatment of people with advanced or metastatic cancers with an APC or AXIN1 mutation.
Treatment
Study for metastatic colorectal cancer that has not yet been treated
Studying a Combination of Three Drugs to Treat Previously Untreated Metastatic Colorectal Cancer which Is MSI-High and Has a BRAF V600E Mutation
This study is being done to learn about the effects of using three study medicines together as treatment for metastatic colorectal cancer that has been previously untreated.
Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting
Comparing a Combination of Drugs for Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting
This study will compare a combination of drugs for people who have HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting.
Treatment
Hispanic and Latino people diagnosed with colorectal cancer
Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)
The ENLACE study will learn more about colorectal cancer in Hispanic people so that treatment can be improved. Results may help your doctor choose your treatment and help you find out if you are eligible for a clinical trial. Your results may also help family members understand their cancer risks.
Treatment
Treatment study for people with advanced cancers
Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors
This study is looking at the effectiveness of an immunotherapy, pembrolizumab, in treating people who have been diagnosed with advanced solid tumors that have progressed on standard-of-care therapy.
Treatment
Cancer treatment study for people with advanced solid tumors
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Treatment
Stage 4 colorectal cancer
Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer
The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus four other treatments in patients with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic (stage IV) Colorectal Cancer.
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.
Both Nivolumab and Relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.
Treatment
Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study
This study is for people with metastatic colorectal cancer. The study will compare how well treatment with a combination of chemotherapy agents and an immunotherapy agent works compared with treatment using an immunotherapy agent alone. This study is focused on patients who are determined to be mismatch-repair deficient (dMMR) or have an MSI-H diagnosis, which are commonly seen in people with Lynch syndrome.
Treatment
People with metastatic colorectal cancer that is MSI-High
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)
The purpose of this study is to compare the benefit of the combination of immunotherapy agents Nivolumab plus Ipilimumab in patients who have Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer versus using Nivolumab as a single therapy or chemotherapy.
Additional Results on Clinicaltrials.gov Treatment + Colorectal Cancer + Stage 4
128 results
Research Search Tool Sponsored By:
